151 related articles for article (PubMed ID: 23914832)
1. Fatal cardiac and renal allograft rejection with lenalidomide therapy for light-chain amyloidosis.
Meyers DE; Adu-Gyamfi B; Segura AM; Buja LM; Mallidi HR; Frazier OH; Rice L
Am J Transplant; 2013 Oct; 13(10):2730-3. PubMed ID: 23914832
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
Kumar SK; Hayman SR; Buadi FK; Roy V; Lacy MQ; Gertz MA; Allred J; Laumann KM; Bergsagel LP; Dingli D; Mikhael JR; Reeder CB; Stewart AK; Zeldenrust SR; Greipp PR; Lust JA; Fonseca R; Russell SJ; Rajkumar SV; Dispenzieri A
Blood; 2012 May; 119(21):4860-7. PubMed ID: 22504925
[TBL] [Abstract][Full Text] [Related]
3. Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report.
Walavalkar V; Adey DB; Laszik ZG; Jen KY
Transplant Proc; 2018 Apr; 50(3):873-876. PubMed ID: 29661456
[TBL] [Abstract][Full Text] [Related]
4. Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma.
Lum EL; Huang E; Bunnapradist S; Pham T; Danovitch G
Am J Kidney Dis; 2017 May; 69(5):701-704. PubMed ID: 28189378
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
Dinner S; Witteles W; Afghahi A; Witteles R; Arai S; Lafayette R; Schrier SL; Liedtke M
Haematologica; 2013 Oct; 98(10):1593-9. PubMed ID: 23716538
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA
Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702
[TBL] [Abstract][Full Text] [Related]
7. A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.
Nair R; Gheith S; Popescu D; Agostino NM
Int J Clin Exp Pathol; 2014; 7(5):2683-9. PubMed ID: 24966987
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.
Palladini G; Russo P; Milani P; Foli A; Lavatelli F; Nuvolone M; Perlini S; Merlini G
Haematologica; 2013 Mar; 98(3):433-6. PubMed ID: 22983583
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
Sanchorawala V; Wright DG; Rosenzweig M; Finn KT; Fennessey S; Zeldis JB; Skinner M; Seldin DC
Blood; 2007 Jan; 109(2):492-6. PubMed ID: 16960148
[TBL] [Abstract][Full Text] [Related]
12. Sudden death possibly related to lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition disease.
Finsterer J; Höftberger R; Stöllberger C; Wöhrer A; Regele H
J Oncol Pharm Pract; 2013 Jun; 19(2):170-4. PubMed ID: 22504167
[TBL] [Abstract][Full Text] [Related]
13. [Immunomodulatory drugs in the treatment of primary systemic light chain amyloidosis].
Charliński G; Wiater E; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Apr; 32(190):217-20. PubMed ID: 22708276
[TBL] [Abstract][Full Text] [Related]
14. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Dispenzieri A; Dingli D; Kumar SK; Rajkumar SV; Lacy MQ; Hayman S; Buadi F; Zeldenrust S; Leung N; Detweiler-Short K; Lust JA; Russell SJ; Kyle RA; Gertz MA
Am J Hematol; 2010 Oct; 85(10):757-9. PubMed ID: 20872958
[TBL] [Abstract][Full Text] [Related]
15. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
Dispenzieri A; Lacy MQ; Zeldenrust SR; Hayman SR; Kumar SK; Geyer SM; Lust JA; Allred JB; Witzig TE; Rajkumar SV; Greipp PR; Russell SJ; Kabat B; Gertz MA
Blood; 2007 Jan; 109(2):465-70. PubMed ID: 17008538
[TBL] [Abstract][Full Text] [Related]
16. [Current treatment of AL amyloidosis].
Desport E; Moumas E; Abraham J; Delbès S; Lacotte-Thierry L; Touchard G; Fermand JP; Bridoux F; Jaccard A
Nephrol Ther; 2011 Nov; 7(6):467-73. PubMed ID: 21497573
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory drugs in AL amyloidosis.
Jelinek T; Kufova Z; Hajek R
Crit Rev Oncol Hematol; 2016 Mar; 99():249-60. PubMed ID: 26806146
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
[TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of Amyloid Light-chain Amyloidosis in a Charcot-Marie-Tooth Disease Patient with Lenalidomide, Cyclophosphamide, and Dexamethasone.
Kikukawa Y; Hata H; Ueda M; Yamashita T; Nasu S; Ide K; Ueno S; Ando Y; Mitsuya H; Okuno Y
Intern Med; 2016; 55(18):2707-12. PubMed ID: 27629972
[TBL] [Abstract][Full Text] [Related]
20. Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.
Jimenez-Zepeda VH; Vajpeyi R; John R; Trudel S
Int J Hematol; 2012 Jul; 96(1):125-31. PubMed ID: 22573235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
